125 related articles for article (PubMed ID: 33370022)
1. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis.
Sonbol MB; Saad AM; Gonzalez-Velez M; Starr J; Halfdanarson TR
Pancreas; 2021 Jan; 50(1):47-53. PubMed ID: 33370022
[TBL] [Abstract][Full Text] [Related]
2. Competing Mortality in Patients With Neuroendocrine Tumors.
Low SK; Giannis D; Bahaie NS; Trong BLH; Moris D; Huy NT
Am J Clin Oncol; 2019 Aug; 42(8):668-674. PubMed ID: 31343423
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
5. Short-term mortality risks among patients with non-metastatic bladder cancer.
Zhai M; Tang C; Li M; Chen X; Jin Y; Ying X; Tang Z; Wang X; Wu Y; Sun C; Chen K; Guo X
BMC Cancer; 2020 Nov; 20(1):1148. PubMed ID: 33238972
[TBL] [Abstract][Full Text] [Related]
6. Causes of death in long-term bladder cancer survivors: A population-based study.
Kong J; Diao X; Diao F; Fan X; Zheng J; Yan D; Huang J; Qin H; Lin T
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e167-e174. PubMed ID: 31111675
[TBL] [Abstract][Full Text] [Related]
7. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
8. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
9. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
10. Second primary cancers and survival among neuroendocrine tumor patients.
Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
[TBL] [Abstract][Full Text] [Related]
11. Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study.
Kamath GR; Kim MK; Taioli E
Pancreas; 2019 Feb; 48(2):161-168. PubMed ID: 30589832
[TBL] [Abstract][Full Text] [Related]
12. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
[TBL] [Abstract][Full Text] [Related]
13. Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Vora HS; Vohra NA; Zervos EE
Am Surg; 2016 Aug; 82(8):737-42. PubMed ID: 27657591
[TBL] [Abstract][Full Text] [Related]
14. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
15. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study.
Cai JS; Chen HY; Lu YF; Yu RS
Future Oncol; 2020 Jan; 16(2):4369-4379. PubMed ID: 31802701
[No Abstract] [Full Text] [Related]
16. Neuroendocrine tumor epidemiology: contrasting Norway and North America.
Hauso O; Gustafsson BI; Kidd M; Waldum HL; Drozdov I; Chan AK; Modlin IM
Cancer; 2008 Nov; 113(10):2655-64. PubMed ID: 18853416
[TBL] [Abstract][Full Text] [Related]
17. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
[TBL] [Abstract][Full Text] [Related]
18. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database.
Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G
BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241
[TBL] [Abstract][Full Text] [Related]
19. Causes of death after breast cancer diagnosis: A US population-based analysis.
Afifi AM; Saad AM; Al-Husseini MJ; Elmehrath AO; Northfelt DW; Sonbol MB
Cancer; 2020 Apr; 126(7):1559-1567. PubMed ID: 31840240
[TBL] [Abstract][Full Text] [Related]
20. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.
Elmehrath AO; Afifi AM; Al-Husseini MJ; Saad AM; Wilson N; Shohdy KS; Pilie P; Sonbol MB; Alhalabi O
JAMA Netw Open; 2021 Aug; 4(8):e2119568. PubMed ID: 34351403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
